- Douglas R Galasko, University of California, San Diego
- Todd E Golde, University of Florida
- Philip Scheltens, VU University Medical Center
Affiliated to Alzheimer's Disease International (ADI), London, United Kingdom
Alzheimer's Disease International is the international federation of national Alzheimer organisations and global voice for dementia, leading and unifying the dementia community to provide global solutions to a global epidemic.
Brivaracetam, but not ethosuximide, was shown to reverse memory impairments in an Alzheimer’s disease (AD) mouse model, confirming a therapeutic role of anticonvulsant drugs targeting synaptic vesicle protein 2A across AD mouse models.
Two-dimensional in vivo Localized COrrelated SpectroscopY (L-COSY) can identify which neurochemicals differ in professional athletes with repetitive brain trauma in comparison to healthy controls.
Alterations in monoaminergic neurotransmitters contribute differently to the neurochemical pathophysiology of depression and psychosis in dementia with Lewy bodies (DLB) compared to Alzheimer’s disease (AD).
Lyketsos and colleagues review the current literature on the phenomenology and diagnosis, neurobiology, and treatment approaches for several key behavioral phenotypes in Alzheimer’s disease.
As part of the cerebral multi-morbidity series, Baker and Götz review the contribution that transgenic animal models have made to a better mechanistic understanding of the causes and consequences of co- or multi-morbidity.
Elevated cerebrovascular resistance (CVRi) in the very-old is associated with greater cerebrovascular disease burden and poorer cognitive function within regions associated with Alzheimer’s disease, demonstrating the potential of CVRi as a potential vascular biomarker.
David M Cash, Jonathan D Rohrer, Natalie S Ryan, Sebastien Ourselin, Nick C FoxAlzheimer's Research & Therapy 2014, 6:87 (20 December 2014)
From the blog
Aims & scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases.
Innate immunity in Alzheimer’s disease
Published: 15 April 2015
Last updated: 22 April 2015
The impact of acute and chronic medical disorders on accelerated cognitive decline
Published: 26 February 2015
Last updated: 10 June 2015
The evolving field of traumatic brain injury
What do we currently know about chronic traumatic encephalopathy (CTE) and what are the most important questions in the field? Listen to a free podcast discussing this and more, as part of our special series on Traumatic Brain Injury.
Searching for biomarkers
As part of our special series on Peripheral Biomarkers, listen to a free podcast by Douglas Galasko about the advances and current issues in the search to identify blood biomarkers for Alzheimer's disease.